Pacira Pharmaceuticals Inc (PCRX.OQ)
22 Nov 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|66||2015||Chairman of the Board, Chief Executive Officer|
|56||2016||Chief Financial Officer|
|53||2015||Senior Vice President - Strategy and Corporate Development|
|52||2015||Senior Vice President, Chief Medical Officer|
|43||2014||Chief Administrative Officer, General Counsel, Secretary|
- BRIEF-Pacira announces FDA advisory committee meeting to review sNDA for Exparel
- BRIEF-Pacira Pharmaceuticals reports Q3 non-gaap earnings per share $0.11
- BRIEF-Pacira Pharma to invest up to $25 million in Tela Bio
- BRIEF-Pacira Pharmaceuticals announces FDA acceptance of SNDA
- BRIEF-Point72 Asset Management LP reports a 5 pct passive stake in Pacira Pharmaceuticals